Quick Overview
Most pharma commercial teams know how many calls their reps made last month. They can see email opens, clicks, digital ad impressions, speaker program attendance, and portal visits.
But ask a tougher question — did those interactions actually influence prescribing? — and things get less clear.
The problem usually isn't a lack of data. It's the way the data is stored.
CRM activity might sit in one system, digital engagement in another, and prescription data somewhere else entirely. The same HCP may also have a different identifier in each source. Add different refresh schedules and inconsistent definitions of engagement, and a seemingly simple analysis becomes surprisingly messy.
Still, connecting these datasets is worth doing.
When it works, commercial teams can see which interactions are associated with changes in NBRx and TRx, which HCPs are responding, and where field or marketing resources may be better spent. It also creates a stronger foundation for HCP targeting, helping teams prioritize physicians based on prescribing potential, engagement behavior, and likely response.
For pharma companies operating in competitive markets, including Boston's life sciences ecosystem, this type of commercial analytics Boston can support more precise field planning, omnichannel engagement, and resource allocation.
This guide breaks down a practical way to connect omnichannel HCP engagement with prescribing outcomes, from resolving HCP identities to choosing an attribution method and validating the results.
Table of Contents
Why Connecting Engagement to Prescribing Data Is Difficult
What Does Connecting Engagement to Prescribing Actually Mean?
Step 1: Resolve HCP Identity Across Data Sources
Step 2: Create a Consistent Definition of Engagement
Step 3: Select the Right Linking Method
Step 4: Account for Time Lag and Confounding Factors
Step 5: Turn the Analysis Into an Ongoing Dashboard
The L.I.N.K. Framework
Perceptive Analytics' Approach
FAQs
Why Connecting Engagement to Prescribing Data Is Difficult
Pharma companies aren't short on data.
A typical commercial organization may have:
CRM activity from field representatives
Email engagement from marketing platforms
Digital advertising data
Speaker program attendance
HCP portal activity
Claims and prescription data
Market access information
Specialty pharmacy data
Each dataset answers a different question. The trouble starts when you try to connect them.
Consider a simple example.
A physician receives two rep visits in March. In April, their TRx increases by 8%.
Did the rep visits cause the increase?
Maybe. But maybe the physician had already started prescribing more in February. Or a competitor had a supply issue. Or the product received better formulary access. Or another marketing channel reached the physician during the same period.
That's why a basic before-and-after comparison can be misleading.
McKinsey research on analytics-enabled omnichannel commercial models has reported potential gains such as a 5–10% revenue uplift, 10–20% improvement in marketing efficiency, a 3–5% increase in active prescribers, and higher HCP satisfaction for companies using these approaches effectively.
One example from the research involved a global pharma company in Germany. The company brought together 14 datasets to build individual-level HCP segmentation for an immunology biologic. The work led to 30–40% call reallocation and an estimated 7–15% increase in prescribing interest.
The opportunity is clear. But getting there takes more than putting all the files into one database.What Does Connecting Engagement to Prescribing Actually Mean?
Connecting engagement to prescribing isn't just a matter of matching a list of HCPs with their prescription numbers.
There are a few questions you need to answer first:
Who exactly is the HCP in each dataset?
What counts as an engagement?
How long after an interaction should you look for a prescribing change?
What other factors could have influenced that change?
How will you know whether the engagement made a difference?
Take the earlier example of the physician whose TRx increased by 8%.
If the physician had received several interactions before the increase, assigning the entire change to the last rep visit wouldn't make much sense.
A stronger analysis connects four pieces:
Identity: Is this the same HCP across all datasets?
Engagement: What actually happened between the brand and the HCP?
Timing: How much time passed before prescribing changed?
Validation: Did similar HCPs who weren't exposed show the same change?
That last piece is easy to overlook. A trend can look impressive until you compare it with what was happening among comparable HCPs.Step 1: Resolve HCP Identity Across Every Data Source
Before worrying about attribution models, fix the identity problem.
An HCP might appear under one practice address in CRM and another in a claims dataset. They may have changed organizations or be associated with several practice locations. Some vendor feeds may also use their own IDs.
If those records aren't matched correctly, the analysis starts with the wrong people.
A practical identity-resolution process should include:
Using NPI as an anchor identifier where available
Matching names and addresses across datasets
Reconciling specialty information
Mapping different practice and organization IDs
Tracking HCP moves between practices
Identifying duplicate records
Maintaining a central HCP reference table
The last one is especially useful.
Without a shared reference table, different teams may create their own matching rules. Marketing might have one HCP universe, sales another, and analytics a third.
That gets confusing very quickly.
A simple example
Suppose Dr. Patel appears in the CRM as:
Dr. R. Patel — ABC Medical Group
The claims data lists:
Rahul Patel, MD — Patel Family Practice
If the systems don't recognize these as the same person, the five rep visits recorded in CRM won't be connected to the prescriptions in the claims data.
The statistical model isn't the problem here. The records simply aren't joined correctly.Step 2: Standardize What "Engagement" Means
Ask five different teams what an "engaged HCP" is, and you may get five answers.
For a sales team, it could mean a completed face-to-face call.
For marketing, it might mean an email click.
For a digital team, an ad impression could count.
Those aren't equivalent signals.
Before doing any analysis, agree on a common engagement taxonomy.
Engagement Type
Typical Data Source
Illustrative Signal Strength
In-person rep detail
CRM
High
Speaker program attendance
Event platform
High
Peer or KOL interaction
CRM + event platform
Medium–High
Email click
Marketing automation
Medium
Email open
Marketing automation
Low–Medium
Portal visit
Web analytics
Low–Medium
Digital ad impression
Ad network/DSP
Low
The exact weighting will depend on the brand and therapeutic area.
An email open, for example, tells you that the message was opened. It doesn't tell you that the physician seriously considered the content or changed their prescribing decision because of it.
The same goes for digital impressions. Seeing an ad is not the same as having a meaningful commercial interaction.
Some teams may choose to create an engagement score. That's fine, as long as the logic is documented and stays consistent across teams.
Also decide who owns the taxonomy. Otherwise, six months into a campaign, someone changes the definition of "engaged" and suddenly your historical comparisons don't line up.
- Step 3: Select the Right Linking Method Once the data is cleaned up, you need to decide how strongly you want to connect engagement with prescribing. There are three common approaches. Method How It Works Best For Main Limitation Rules-based tagging Flags a prescribing change after a qualifying interaction within a defined period Early pilots and smaller teams Doesn't establish causality Test-and-control analysis Compares engaged HCPs with similar, unexposed HCPs Brands looking for defensible lift estimates Needs a reliable comparison group Statistical/ML attribution Models interaction patterns while accounting for other factors Mature analytics programs Requires stronger data and ongoing maintenance
Rules-based tagging
This is usually the easiest starting point.
For example:
Flag an HCP if they receive a qualifying engagement and their NBRx increases within 60 days.
It's straightforward and easy to explain to a brand team.
The catch? It doesn't prove that the engagement caused the increase.
Think of it as a useful first signal, not the final answer.
Test-and-control analysis
A more robust approach is to compare engaged HCPs with similar HCPs who weren't exposed to the same intervention.
For example:
Group A receives a campaign.
Group B has similar characteristics but doesn't receive it.
Both groups are monitored over the same period.
The difference in prescribing movement is used to estimate incremental lift.
This gives the commercial team a much stronger basis for saying, "prescribing increased more among the exposed group."
Statistical and ML attribution
Once enough historical data is available, the analysis can become more sophisticated.
A model might consider:
Number of rep visits
Email engagement
Digital exposure
Speaker program participation
HCP specialty
Historical prescribing
Patient volume
Market access
Competitor activity
Seasonal patterns
Instead of looking at one interaction in isolation, the model can examine sequences.
For instance, perhaps three digital exposures followed by a rep discussion are more strongly associated with a prescribing change than either channel alone.
That's the kind of pattern basic reporting tends to miss.
Step 4: Account for Time Lag and Other Factors
Prescribing behavior doesn't always change immediately after an HCP interaction.
A physician might have several conversations with a brand before changing their prescribing habits. In another case, the change could happen weeks after a single important interaction.
So don't automatically treat the same week as the attribution window.
Set a realistic attribution window
Depending on the product and therapeutic area, teams might test 30-, 60-, or 90-day windows.
The key word is test.
If the model uses a 30-day window simply because 30 days was convenient, the results may not mean much. Look at historical behavior and determine what timing makes sense for the brand.
Check formulary and access changes
Imagine TRx rises 12% after a series of rep visits.
Looks good.
Then you discover the product moved to a preferred formulary tier during the same period.
That access change could explain a large part of the increase.
Market access variables should therefore be part of the analysis wherever they're relevant.
Control for seasonality
Seasonality can create false signals.
Respiratory products, for example, can see predictable changes in prescribing during certain parts of the year. If you compare March with January without accounting for those patterns, you may give commercial activity credit for a change that was largely seasonal.
Watch for multiple touchpoints
HCPs rarely interact with one channel at a time.
A physician could receive an email on Monday, see a digital ad on Tuesday, meet a rep on Thursday, and attend a speaker program two weeks later.
Which one caused the prescribing change?
You often can't say with certainty.
That's why looking at the full interaction sequence is usually more useful than giving 100% of the credit to the last touchpoint.Step 5: Turn the Analysis Into an Ongoing Dashboard
A model isn't very useful if the results end up in a quarterly PowerPoint deck that nobody looks at again.
Commercial teams need the findings while they're making decisions.
A useful dashboard might show:
HCPs showing positive prescribing movement after engagement
Channels associated with stronger responses
HCP segments receiving high outreach but showing limited response
Interaction sequences linked with better outcomes
Changes in response over time
Opportunities to shift field or marketing resources
The output should be practical.
Instead of simply saying:
HCP engagement score: 87
the system could provide something closer to:
"This HCP has responded more strongly to in-person interactions than email. Consider prioritizing field engagement."
That's something a rep or brand manager can actually use.
Keep the model fresh
Commercial behavior changes.
HCP preferences change. Competitors launch new campaigns. Formulary positions move. A product enters a new stage of its lifecycle.
A model trained on last year's behavior may not tell you much about what's happening now.
Weekly monitoring can help identify changes early, while more formal validation can be done quarterly or at another cadence that fits the brand.The L.I.N.K. Framework
If you need a simple way to explain the process internally, use the L.I.N.K. framework.
L — Link identities
Make sure engagement and prescribing records point to the same HCP.
Don't start modeling until this is reasonably reliable.
I — Integrate the data
Bring CRM, digital engagement, speaker programs, prescribing, claims, and relevant access data into a common analytical environment.
The goal isn't necessarily one giant enterprise warehouse. A focused data mart can be enough for an initial brand-level program.
N — Normalize definitions and time windows
Agree on what counts as engagement.
Then define the attribution windows and rules for handling seasonality, market access changes, and multiple interactions.
K — Keep validating
This isn't a one-and-done exercise.
Test lift estimates against an appropriate comparison group. Review the model as new data arrives. If the results stop matching what commercial teams see in the field, investigate why.
A model shouldn't get a free pass just because it worked well last year.Perceptive Analytics' Approach
Perceptive Analytics views the connection between HCP engagement and prescribing as both an analytics problem and a data engineering problem.
That distinction is useful because the modeling usually gets most of the attention.
In practice, the less glamorous work — identity resolution, data integration, taxonomy design, and governance — often determines whether the final analysis is trustworthy.
The same applies when deciding where commercial resources should go. A team needs to know which physicians matter, what interactions they've already had, and how their behavior is changing before it can make a sensible next-action recommendation.
Perceptive Analytics' life sciences commercial analytics work focuses on bringing these disconnected datasets together and turning them into decisions that commercial teams can act on.
The goal isn't another dashboard for the sake of having another dashboard.
It's to help answer practical questions:
Which HCPs are responding?
Which channels appear to be working?
Where are we spending effort without seeing much movement?
What should the field or marketing team do next?
That shift — from measuring activity to understanding its relationship with prescribing behavior — is where the analysis becomes genuinely useful.FAQs
Do we need a full data warehouse before connecting engagement and prescribing data?
No.
A focused data mart or governed analytical layer can be enough to get started with one brand or therapeutic area.
What matters most is that the relevant datasets can be joined consistently and that everyone is working from the same HCP identity.
How much historical data is needed?
There isn't one magic number.
A year or more of linked engagement and prescribing data can provide a stronger basis for identifying recurring patterns. A simple pilot, however, can start with less.
The amount you need also depends on prescribing frequency, the size of the HCP population, and the type of analysis you're trying to run.
Can smaller pharma companies do this without a large data science team?
Yes.
You don't necessarily need a large in-house data science organization to begin.
A focused project around one product, a specific HCP segment, or a small number of channels can be a practical starting point. The bigger challenge is usually getting the data connected and the identity matching right.
What's the difference between engagement analytics and prescribing behavior analytics?
Engagement analytics tells you what happened.
For example:
How many calls took place?
How many emails were clicked?
How many HCPs attended an event?
Prescribing behavior analytics asks a different question:
What happened to prescribing after those interactions, and which engagement patterns were associated with the change?
How can teams avoid overstating the impact of one channel?
Don't give all the credit to the last interaction.
Use an appropriate attribution window, account for factors such as formulary changes and seasonality, and compare exposed HCPs with a suitable control or comparison group.
A raw before-and-after chart isn't enough to establish causality.
Is this useful only for established brands?
No.
It can be particularly useful during a product launch because early engagement and prescribing signals can give commercial teams an indication of whether field and marketing activity is moving in the expected direction.
Can this work be outsourced?
Yes.
An external analytics partner can support identity resolution, data integration, attribution modeling, governance, and dashboard development.
For teams that don't have all of these capabilities internally, bringing in specialist support can shorten the path from disconnected data to a working commercial analytics program.
Final Takeaway
The point of connecting engagement data with prescribing data isn't to prove that every rep call or email caused a prescription.
Commercial behavior is rarely that simple.
The real value comes from building a reliable connection between who was engaged, what happened, when it happened, and how prescribing changed afterward.
Start with clean HCP identities. Define engagement consistently. Choose an attribution method that matches the quality of your data. Then keep testing the results against what is actually happening in the market.
Once that foundation is in place, the analysis can move beyond counting activity and start helping commercial teams make better decisions about where to focus their next interaction.
Top comments (0)